ClinicalTrials.gg
Active, not recruitingNCT07477704ASCEND-QWUpdated Oct 15, 2026

A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia

A Phase 2 interventional study of Alirocumab in Hypercholesterolemia, sponsored by Regeneron Pharmaceuticals. Active, not recruiting at 34 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment

Updated Oct 15, 2026Now Active, not recruitingEnrollment updated+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
438
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 43 studies testing alirocumab in Hypercholesterolemia — 1 open to participants now, 2 under way, none of them phase 3. alirocumab · Hypercholesterolemia.

Enrollment
11th of 43
438 · median 107
Started
2026
with 1 other
Phase 2
9 of 43
none open now
Registered
42nd of 43
by date
Lead sponsor
11 of 43
Regeneron Pharmaceuticals

Among the 43 studies testing alirocumab in Hypercholesterolemia, this one is the 11th largest by enrollment, is one of 2 that started in 2026, is one of 9 in phase 2, and was the 42nd registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

1 of the 43 studies testing alirocumab in Hypercholesterolemia is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About alirocumab

alirocumab: first FDA approval 2015 (PRALUENT), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing alirocumab in Hypercholesterolemia, or all of them as a file.
02

Study summary

This study is researching an experimental drug called alirocumab, referred to as "study drug". In the United States, alirocumab is approved for the treatment of hypercholesterolemia (high blood cholesterol levels).

The aim of the study is to see how safe and effective alirocumab is when given weekly to adult participants who have hypercholesterolemia.

The study is looking at several other research questions, including:

  • What side effects may happen from taking the study drug once a week
  • How much study drug is in the blood at different times
03

Conditions studied

  • Hypercholesterolemia

Keywords

  • Obesity
  • Elevated Low-Density Lipoprotein Cholesterol (LDL-C) Levels
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

1. Participant has elevated LDL-C level, as defined in the protocol

Key Exclusion Criteria:

  1. Participant plans to initiate or change dose of lipid-lowering therapy
  2. Use of any PCSK9 inhibitors

NOTE: Other Protocol-Defined Inclusion/Exclusion Criteria Apply

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
438 participants (actual)

Study arms

  • Experimental
    Arm 1 - Low Dose

    Drug: Alirocumab

  • Experimental
    Arm 2 - Medium Dose

    Drug: Alirocumab

  • Experimental
    Arm 3 - High Dose

    Drug: Alirocumab

  • Experimental
    Arm 4 - Control Dose

    Drug: Alirocumab

Interventions

  • Administered per the protocol

    Also known as: Praluent®, REGN727, SAR236553

06

What researchers measure

Primary outcomes

  1. Percent change in LDL-C

    Time frame: From Baseline through Week 12

Secondary outcomes

  1. Concentrations of total alirocumab in serum

    Time frame: Through Week 20

  2. Concentrations of free Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) in serum

    Time frame: Through Week 20

  3. Percent change in LDL-C

    Time frame: From Baseline through Week 8

  4. Percent change in total cholesterol

    Time frame: From Baseline through Week 12

  5. Percent change in non-High-Density Lipoprotein-Cholesterol (HDL-C)

    Time frame: From Baseline through Week 12

  6. Percent change in HDL-C

    Time frame: From Baseline through Week 12

  7. Percent change in triglycerides

    Time frame: From Baseline through Week 12

  8. Percent change in Apolipoprotein B (ApoB)

    Time frame: From Baseline through Week 12

  9. Occurrence of Treatment-Emergent Adverse Events (TEAEs)

    Time frame: Through Week 20

  10. Severity of TEAEs

    Time frame: Through Week 20

07

Study locations

34 sites
08

References and documents

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy

Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Dec 2026, 6 months after the start.

Of 41 industry-sponsored phase 2 interventional studies under Hypercholesterolemia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 14. This study's planned 6 months is below that.

Counting every sponsor, half of 48 studies reached it within 10 months; a quarter within 7 and three quarters within 18.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2026
First posted
Mar 17, 2026
StartActual
Jun 17, 2026
Primary completionEst.
Dec 29, 2026
CompletionEst.
Feb 23, 2027
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 15, 2026
Sites
1 site added, 1 site removed
Show site
  • Flourish Research, Legacy Oaks Tower · San Antonio, United States
Show 1 removed
  • Flourish Research - San Antonio Medical Trials · San Antonio, United States
Oct 15, 2026
Enrollment
420 (estimated)→438 (actual)
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Recruiting→Active, not recruiting
    1 site added, 1 site removed
    Show site
    • Flourish Research, Legacy Oaks Tower · San Antonio, United States
    Show 1 removed
    • Flourish Research - San Antonio Medical Trials · San Antonio, United States
    Enrollment 420 (estimated)→438 (actual)
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07477704
Responsible party
Sponsor
First posted
Mar 17, 2026
Start date
Jun 17, 2026
Primary completion
Dec 29, 2026 (estimated)
Completion
Feb 23, 2027 (estimated)
Last update
Oct 15, 2026

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alirocumab

Start the discussion